Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05 2021 - 8:00AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab-vikg for
use in retinal indications, today announced that Lawrence A.
Kenyon, President, CEO and CFO of Outlook Therapeutics, will
present in a fireside chat at the H.C. Wainwright BioConnect 2021
Virtual Conference taking place January 11-14, 2021.
A video webcast of the fireside chat will be
available for viewing on-demand beginning Monday, January 11, 2021,
at 6:00 AM ET for those registered for the event and accessible on
the Events page of the Investors section of the Outlook
Therapeutics website, outlooktherapeutics.com.
For more information about the event, please
visit the conference website here.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a late clinical-stage
biopharmaceutical company working to develop ONS-5010/LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab-vikg for use in retinal indications, including wet
AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics
expects to commercialize it as the first and only FDA-approved
ophthalmic formulation of bevacizumab-vikg for use in treating a
range of retinal diseases in the United States, United Kingdom,
Europe, Japan, China and other markets. Outlook Therapeutics
expects to file ONS-5010 with the U.S. FDA as a new BLA under the
PHSA 351(a) regulatory pathway, initially for wet AMD. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:
Harriet UllmanAssistant Vice PresidentLaVoieHealthScienceT:
617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:
Jenene ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2023 to Apr 2024